Xagenic was a Toronto-based molecular diagnostics company developing a fully automated, chip-based platform for lab-free, point-of-care testing with results in under 30 minutes, targeting infectious diseases and potentially cancer detection.[1][2][5] The technology used patented nanostructured microelectrodes for rapid nucleic acid detection (DNA/RNA), serving clinicians, patients, and healthcare systems by enabling on-site pathogen screening in physician offices or at bedside, reducing anxiety, treatment delays, and lab costs.[2][3] It addressed unmet needs in diagnostics by automating complex lab processes into disposable cartridges, achieving early recognition like the 2014 Frost & Sullivan award, and securing $20 million in Series B funding plus provincial investments.[1][6][7]
Founded in 2010, Xagenic emerged from University of Toronto research by Dr. Shana Kelley, a renowned scientist and professor who invented the nanotechnology-based microelectrodes for ultrasensitive sensors.[2][3] The idea stemmed from breakthroughs in nanoscale engineering to create fast, simple molecular tests bypassing skilled technicians and lengthy lab workflows.[2] Early traction included a $1 million investment from Ontario's Ministry of Research via MaRS Innovation in 2011 to commercialize the tech, followed by support from investors like BDC Capital, Domain Associates, CTI Life Sciences Fund, and Ontario Capital Growth Corporation.[1][2]
Xagenic rode the wave of point-of-care diagnostics and nanotechnology convergence, accelerating amid demands for faster pathogen detection post-global health crises and rising healthcare decentralization.[2][3] Timing aligned with shifts toward miniaturized, field-deployable biotech, fueled by market forces like strained lab systems and needs for on-site testing in infectious disease and oncology.[1][2] Its influence shaped the ecosystem by pioneering chip-based molecular tools, influencing defense and security applications via asset acquisition, and demonstrating academic-to-commercial pathways through Toronto's innovation hubs like MaRS.[2][3]
By 2018, General Atomics acquired Xagenic's assets, integrating its bio-sensor tech into GA-EMS operations in California under Dr. Graham Jack to advance microelectronics for defense, signaling a pivot from pure diagnostics to ruggedized, deployable systems.[3] Next steps likely involve scaling cartridge manufacturing and sensor miniaturization for national security and beyond-lab health uses. Trends like AI-enhanced diagnostics and portable biotech will propel this legacy, evolving Xagenic's innovations to bolster resilient supply chains in global health and defense ecosystems—transforming bedside breakthroughs into frontline tools.[3]
Xagenic has raised $38.0M in total across 2 funding rounds.
Xagenic's investors include Amplitude VC, Domain Associates.
Xagenic has raised $38.0M across 2 funding rounds. Most recently, it raised $12.0M Series B in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $12.0M Series B | Amplitude VC, Domain Associates | |
| Jul 1, 2014 | $26.0M Series B | Amplitude VC, Domain Associates |
